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Volume 6Available online 27 November 2020Background: Cancer patients are at increased risk of death from severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Cancer and its treatment affect many haematological and biochemical parameters, therefore we
analysed these prior to and during coronavirus disease 2019 (COVID-19) and correlated them with outcome.
Patients and methods: Consecutive patients with cancer testing positive for SARS-CoV-2 in centres throughout the
United Kingdom were identified and entered into a database following local governance approval. Clinical and
longitudinal laboratory data were extracted from patient records. Data were analysed using ManneWhitney U test,
Fisher's exact test, Wilcoxon signed rank test, logistic regression, or linear regression for outcomes. Hierarchical
clustering of heatmaps was performed using Ward's method.
Results: In total, 302 patients were included in three cohorts: Manchester (n ¼ 67), Liverpool (n ¼ 62), and UK (n ¼
173). In the entire cohort (N ¼ 302), median age was 69 (range 19-93 years), including 163 males and 139 females; of
these, 216 were diagnosed with a solid tumour and 86 with a haematological cancer. Preinfection lymphopaenia,
neutropaenia and lactate dehydrogenase (LDH) were not associated with oxygen requirement (O2) or death.
Lymphocyte count (P < 0.001), platelet count (P ¼ 0.03), LDH (P < 0.0001) and albumin (P < 0.0001) significantly
changed from preinfection to during infection. High rather than low neutrophils at day 0 (P ¼ 0.007), higher
maximal neutrophils during COVID-19 (P ¼ 0.026) and higher neutrophil-to-lymphocyte ratio (NLR; P ¼ 0.01) were
associated with death. In multivariable analysis, age (P ¼ 0.002), haematological cancer (P ¼ 0.034), C-reactive
protein (P ¼ 0.004), NLR (P ¼ 0.036) and albumin (P ¼ 0.02) at day 0 were significant predictors of death. In the
Manchester/Liverpool cohort 30 patients have restarted therapy following COVID-19, with no additional
complications requiring readmission.
Conclusion: Preinfection biochemical/haematological parameters were not associated with worse outcome in cancer
patients. Restarting treatment following COVID-19 was not associated with additional complications. Neutropaeniaondence to: Dr Rebecca Lee, Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. Tel: þ44-
000
ebecca.lee-3@manchester.ac.uk (R.J. Lee).
ontribution.
29/© 2020 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND
p://creativecommons.org/licenses/by-nc-nd/4.0/).
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due to cancer/treatment is not associated with COVID-19 mortality. Cancer therapy, particularly in patients with solid
tumours, need not be delayed or omitted due to concerns that treatment itself increases COVID-19 severity.
Key words: COVID-19, cancer, SARS-CoV-2INTRODUCTION
Coronavirus disease 2019 (COVID-19) represents an un-
precedented global health challenge. A diverse spectrum of
clinicopathological syndromes have been reported, ranging
from asymptomatic cases to multiorgan failure and death.1
Patients with cancer are at significantly increased risk of
COVID-19 and severe complications, including need for
invasive ventilation and death2,3 with reported fatality rates
of 10%-30%,3-5 with a recent meta-analysis of 18 650 pa-
tients with COVID-19 and cancer reporting a probability of
death of 25.6%.6 Older patients, those with multiple
comorbidities and male sex appear to be at a particularly
high risk for poor outcomes.2,4,5,7
Large-scale studies in the general population have iden-
tified a number of clinical and pathological factors associ-
ated with adverse outcomes in patients with confirmed
COVID-19.8,9 In the general population, patients with neu-
trophilia, lymphopaenia, raised C-reactive protein (CRP) and
lactate dehydrogenase (LDH) are significantly more likely to
develop acute respiratory distress syndrome (ARDS).8,10 In
addition to the clinical features of fever, dyspnoea and
cough, commonly observed biochemical abnormalities in
cancer patients with COVID-19 include lymphopaenia, high
levels of CRP and hypoalbuminaemia; however, the prog-
nostic significance of these derangements within an
oncology population has not yet been established.11
In addition to the inherent immunosuppression of cancer
and its therapies, malignancy itself can cause biochemical
abnormalities such as raised LDH/CRP and low albumin. We
aimed to understand whether these abnormalities were
associated with worse outcomes for cancer patients during
COVID-19 illness. We analysed changes in biochemical and
haematological parameters both before and during infec-
tion to identify systemic changes which occur when patients
with cancer become infected with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and correlated them
with measures of severity.
METHODS
Database approval
Institutional approval was obtained following local infor-
mation governance processes for case-note review at each
site in order to establish a database to support wider clinical
decision-making. In line with Health Research Authority
(UK) guidance, database creation to support public health
surveillance and clinical decisions is exempt from Ethics
Committee review, and anonymised data within a database
can be used for research purposes if local governance
approval is obtained.12 Data were fed into other registries
such as the UK Cancer Coronavirus Monitoring Project
(UKCCMP) and ESMO Co-Care registry.4 Patients with ahttps://doi.org/10.1016/j.esmoop.2020.100005cancer diagnosis testing PCR positive for SARS-CoV-2 were
included. Asymptomatic patients screened prior to planned
surgery were excluded from the database due to insufficient
data; however, asymptomatic patients with nosocomial
infection were included. Longitudinal data were available
from two oncology centres (Manchester and Liverpool).
Data on clinical and laboratory features before and during
SARS-CoV-2 infection were extracted from patient records.
All patient data within the database were pseudoanony-
mised with the key matching the study identity to patient
identities kept at local National Health Service (NHS) sites.
The data were anonymous to the study team performing
the analysis.Study design
A variety of measures were used to provide information
regarding preinfection and during infection parameters. For a
sample size calculation we used a pilot study of 52 patients
fromManchester. Assuming a clinically meaningful difference
betweenmeans of 25mg/l, 1.5 109 g/l, 0.25 109 g/l and 1
g/l for CRP, neutrophils, lymphocytes and albumin, respec-
tively, we estimated that the sample size of 136 patients was
needed to achieve 80% power and with a 5% alpha.
To evaluate chronic preinfection states (CHRONIC), values
were taken as the average results from the previous 6
months up to 14 days (the maximum incubation period of
SARS-CoV-213) prior to COVID-19 diagnosis. We used the
value closest to day 15 preinfection (IMMED) to provide
information about the patient's state just prior to diagnosis
of COVID-19. During infection, we assessed day 0 values
defined as the date of SARS-CoV-2 PCR confirmation. Min-
imum and maximum values were the lowest and highest
values, respectively, during infection defined as day 0-14.
Oxygen requirement (O2) and death were used as measures
of severity of infection. According to clinical assessments
and national guidance,14 due to advanced cancer stage and
frailty of the majority of patients, only a minority would
have benefited from critical organ support and requirement
for intensive care unit (ICU) was not used as an outcome
measure.Statistical analysis
Analysis was performed using SPSS version 21, GraphPad
Prism 8.1.2 and Python Version 3.7. Differences between
groups (O2 and death) were calculated using Wilcoxon
signed rank test (for the change from preinfection to during
infection), ManneWhitney U test and Fisher's exact test,
with the significance level P ¼ 0.05. The effect size was
calculated as common language effect size (CL),15 or odds
ratio (OR) accordingly. Details regarding numbers of patients
included in each analysis and the mean values of each groupVolume 6 - Issue 1 - 2021
Table 1. Characteristics of the total cohort of cancer patients presenting
with coronavirus 2019 (COVID-19)
Characteristic Number (percentage)
Median age (range) 69 (19-93)
Sex
Male 163 (54.0)
Female 139 (66.0)
Comorbidities
Hypertension 95 (31.5)
Chronic obstructive pulmonary disease 38 (12.6)
Diabetes 60 (19.9)
Cardiovascular disease 68 (22.5)
Cancer type
Haematological 86 (28.5)
Solid 216 (71.5)
Cancer stage
Early stage 96 (31.8)
Distant metastases 184 (60.9)
Unknown 22 (7.2)
Therapy within 4 weeks of infectiona
Chemotherapy 117 (38.7)
R. J. Lee et al. ESMO Openare presented in Supplementary Tables S1 and S2, available at
https://doi.org/10.1016/j.esmoop.2020.100005. Heatmaps
were grouped using hierarchical clustering according to
Ward's method, based on values from day 0 to day 7. For
clustering purposes only, the missing values within these days
were imputed using linear interpolation, and filled forward
after the latest value with only the known (not imputed)
values shown on the heatmap. A multivariable analysis for O2
and death for features at day 0 was performed using logistic
regression. For duration of hospitalisation in patients who
died from COVID-19, linear regression was performed.
Missing values in numeric features at day 0 (less than 10%)
were imputed using Bayesian ridge regression. Before that, a
logarithmic transformation was applied to highly skewed
features. Missing values of cancer stage (<10%) were
imputed using logistic regression trained on all remaining
features. In all aforesaid tests P < 0.05 was considered
statistically significant.Targeted therapy 48 (15.8)
Immune therapy 14 (4.6)
a Can have more than one therapy.RESULTS
Clinical characteristics
In the Manchester and Liverpool cohorts 67 and 62 patients
were identified, respectively, with a further 173 patients
identified in the UK cohort. Clinical features of the Man-
chester, Liverpool and UK cohorts are presented in Table 1
and Supplementary Tables S3-S5, available at https://doi.
org/10.1016/j.esmoop.2020.100005. Across the entire
cohort, median age was 69 years, range 19-93, with 163
males and 139 females. Two hundred and sixteen had a
solid tumour and 86 a haematological cancer; 39% (117/
302) of patients received chemotherapy within the 4 weeks
preceding infection, 16% (48/302) received targeted ther-
apy and 4.6% (14/302) immunotherapy [programmed cell
death protein 1/programmed death-ligand 1/cytotoxic T
lymphocyte antigen 4 (PD-1/PD-L1/CTLA-4) inhibitors]. The
rest received radiotherapy, hormone treatment or no active
treatment within the 4 weeks preceding infection. In
Manchester and Liverpool, 99 patients presented to hos-
pital with symptoms of COVID-19, whereas 30 patients
were likely nosocomial infection cases.Clinical outcomes
At time of data cut-off, we grouped patients according to
worst outcome/maximal supportive therapy. In total, 13%
(39/302) of patients were discharged within 24 hours,
without further complications/admissions; 11% (34/302),
already admitted due to complications from cancer and/or
cancer therapy, were incidentally diagnosed during
screening for SARS-CoV-2 infection; 15% (46/302) of pa-
tients were admitted but did not require oxygen therapy;
~23% (70/302) required oxygen and 2% (7/302) were
admitted to ICU; 29% (87/302) died due to COVID-19 with a
further 6% (17/304) dying from non-COVID-19 causes such
as documented cancer progression. Two patients did not
have a specified outcome. Of the patients in the Man-
chester and Liverpool cohorts still alive and on treatment,Volume 6 - Issue 1 - 2021~19% (10/52) continued throughout COVID-19 illness
(either hormone treatment or radiotherapy). A further 58%
(30/52) have restarted therapy [11 targeted therapy, 3
immunotherapy, 14 chemotherapy (including 4 on high-
dose chemotherapy), 2 radiotherapy] at a median of 21
days following positive SARS-CoV-2 test. None of these
patients have had further complications due to SARS-CoV-2,
or readmission within 30-days.Haematological features
To provide a detailed characterisation of the clinical course
of COVID-19 in cancer patients attending hospital, we
examined various haematological characteristics both pre-
infection and during infection.
Lymphocytes. We observed lymphopaenia in 247/286 pa-
tients with data available at diagnosis of COVID-19 (day 0)
in the entire cohort. Haematological parameters are often
affected by cancer and its treatment, therefore in the
Manchester and Liverpool cohort we examined whether
COVID-19 infection affected these compared with each
patient's long-term baseline (average over a 6-month
period ¼ CHRONIC) and immediate baseline (last test
prior to infection ¼ IMMED). The majority of patients (76/
116 with tests available prior to infection) were lympho-
paenic with 76/116 having CHRONIC lymphopaenia. We
therefore examined whether lymphocyte counts were
further reduced during COVID-19 through comparing
CHRONIC and IMMED preinfection counts with their
average lymphocyte counts from the first 7 days of diag-
nosed infection (Figure 1A and B). This revealed that while
patients with cancer are generally lymphopaenic, infection
with SARS-CoV-2 was significantly associated with a further
decrease in counts (Figure 1A: mean 1.59 versus
0.99; P < 0.0001, CL ¼ 0.72 and Figure 1B: 1.50 versushttps://doi.org/10.1016/j.esmoop.2020.100005 3
A B D E
F
G
H
C
0
1
2
3
4
5
10
15
20
25
Lymphocytes
Timepoint
Ly
m
ph
oc
yt
es
 ×
 1
09
/l
Pre During
****
0
5
15
20
25
Lymphocytes
Timepoint
Ly
m
ph
oc
yt
es
 ×
 1
09
/l
Pre During
***
0
200
400
600
800
Platelets
Timepoint
Pl
at
el
et
s 
× 
10
9 /l
Pre During
***
0
200
400
600
800
Platelets
Timepoint
Pl
at
el
et
s 
× 
10
9 /l
Pre During
*
P = 0.004, CL=0.59
P = 0.043, CL=0.56
P = 0.126, CL=0.54
Value at day 0 [× 109/l]
Value at day 0 [× 109/l]
Value at day 0 [× 109/l]
Value at day 0 [× 109/l]
ICU
O2
O2
Figure 1. Longitudinal changes in lymphocytes and platelets.
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R. J. Lee et al. ESMO Open0.99; P < 0.0001, CL ¼ 0. 72). In patients with haemato-
logical cancer, preinfection lymphocyte count was not
significantly different from solid tumours (Supplementary
Figure S1A, available at https://doi.org/10.1016/j.esmoop.
2020.100005; CHRONIC P ¼ 0.18, CL ¼ 0.58 and IMMED
Figure 1B; P ¼ 0.96, CL ¼ 0.48); however, at day 0 of
infection they had significantly lower counts compared with
patients with nonhaematological malignancy (Figure 1C; P ¼
0.004, CL ¼ 0.59). Furthermore, we found that 107/290
patients in the entire cohort had thrombocytopaenia
(<150  109/l) at COVID-19 diagnosis. Again, in the Man-
chester cohort we compared patients' preinfection platelets
(CHRONIC/IMMED) with the average counts during COVID-
19 and found a significant reduction (CHRONIC mean 252
versus 199; P ¼ 0.0008, CL ¼ 0.67; Figure 1D; IMMED mean
236 versus 199; P ¼ 0.03, CL ¼ 0.58; Figure 1E).
Next, we examined whether day 0 lymphocyte count was
associated with different outcomes in the entire cohort
(Figure 1F; Supplementary Table S1, available at https://doi.
org/10.1016/j.esmoop.2020.100005).We observed that low
day 0 lymphocyte count was significantly associated with O2
during COVID-19 (Figure 1F; P ¼ 0.043, CL ¼ 0.56) but not
with death (Figure 1G; P ¼ 0.126, CL ¼ 0.54). Furthermore,
minimum lymphocyte count during day 0-14 of infection
was significantly associated with O2 (Supplementary
Figure S1C, available at https://doi.org/10.1016/j.
esmoop.2020.100005; P ¼ 0.005, CL ¼ 0.61) but not
death (Supplementary Figure S1D, available at https://doi.
org/10.1016/j.esmoop.2020.100005; P ¼ 0.07, CL ¼ 0.56)
in the Manchester/Liverpool cohorts. As many patients
were lymphopaenic due to cancer or cancer treatment prior
to COVID-19, we assessed whether this affected outcome
following infection. Critically, we did not find a significant
association of O2 or death with average (Supplementary
Figure S1E, available at https://doi.org/10.1016/
j.esmoop.2020.100005; P ¼ 0.26; CL ¼ 0.56 and
Supplementary Figure S1F, available at https://doi.org/10.
1016/j.esmoop.2020.100005; P ¼ 0.33; CL ¼ 0.55 O2 and
death, respectively) or day e15 lymphocyte count
(Supplementary Figure S1G and S1H, available at https://
doi.org/10.1016/j.esmoop.2020.100005; P ¼ 0.47; CL ¼
0.52 and P ¼ 0.79; CL ¼ 0.49, O2 and death, respectively).
Neutrophils. We examined whether neutrophil counts
changed during SARS-CoV-2 infection. In the entire cohort
with data available, 57/287 were neutropaenic at baseline
(absolute neutrophil count <2  109/l) with 32 of these
having neutrophils<1  109/l, and 20 patients<0.5  109/l.
In the Manchester cohort, of the 32 patients presenting(A) CHRONIC lymphocyte counts (day 170 to day 15) preinfection versus 7 days du
IMMED (last test pre-infection) versus 7 days during infection in the Manchester cohor
diagnosis of haematological malignancy. (D) CHRONIC platelet counts preinfection vers
count IMMED preinfection versus 7 days during infection in the Manchester cohort (
entire cohort measured at day 0. Discharge, discharged within 24 hours; Inpt for non-
altered by infection; COVID-19 no O2, admitted due to COVID-19 infection but did not r
admitted plus ICU, admitted due to COVID-19 and required intensive care; COVID
oxygen requirement in the entire cohort measured at day 0. (H) Boxplot of lymphocyt
COVID-19, coronavirus disease 2019; ICU, intensive care unit.
Volume 6 - Issue 1 - 2021with neutropaenia at any point from day 14 to 14, 6 were
on chemotherapy and were in treatment nadir, 2 were
neutropaenic while taking palbociclib (CDK4/6 inhibitor)
and 3 patients had a baseline neutropaenia due to hae-
matological cancer. Although patients with haematological
cancer did not have lower CHRONIC neutrophil counts
compared with patients with solid malignancies
(Supplementary Figure S2A, available at https://doi.org/
10.1016/j.esmoop.2020.100005; P ¼ 0.1, CL ¼ 0.66), they
had lower neutrophil counts: both IMMED preinfection
(Supplementary Figure S2B, available at https://doi.org/
10.1016/j.esmoop.2020.100005; P ¼ 0.002, CL ¼ 0.68)
and at day 0 (Supplementary Figure S2C, available at
https://doi.org/10.1016/j.esmoop.2020.100005; P ¼ 0.001,
CL ¼ 0.67). In Manchester, patients with neutropaenia were
given granulocyte colony-stimulating factor (G-CSF). Longi-
tudinal data for the 32 Manchester patients presenting with
neutropaenia are shown in Supplementary Figure S2D,
available at https://doi.org/10.1016/j.esmoop.2020.100005.
Intriguingly, in these patients the drop in neutrophils
occurred close to the time of SARS-CoV-2 test, which for the
majority was when they presented with symptoms and
rapidly improved even without G-CSF support, with a me-
dian neutropaenia duration of 3 days.
As neutropaenia could result in impaired immune
response to SARS-CoV-2, we assessed whether this influ-
enced outcome. Low neutrophil count at diagnosis of
COVID-19 (day 0) was not associated with increased infec-
tion severity in the entire cohort (Figure 2A). By contrast,
we observed a significant association with O2 (Figure 2B;
P < 0.001, CL ¼ 0.65) and death (Figure 2C; P ¼ 0.007, CL ¼
0.60) in patients with a higher neutrophil count at day 0.
Comparison of minimum neutrophil count (Manchester/
Liverpool cohorts) during COVID-19 was not significantly
associated with O2 (Supplementary Figure S2E, available at
https://doi.org/10.1016/j.esmoop.2020.100005; P ¼ 0.38,
CL ¼ 0.54) or death (Supplementary Figure S2F, available at
https://doi.org/10.1016/j.esmoop.2020.100005; P ¼ 0.24,
CL ¼ 0.56). However, higher maximal neutrophil count
(patients given G-CSF excluded, Manchester/Liverpool
cohorts), although not significantly associated with O2
(Supplementary Figure S2G, available at https://doi.org/
10.1016/j.esmoop.2020.100005; P ¼ 0.086, CL ¼ 0.59),
was significantly associated with death (Supplementary
Figure S2H, available at https://doi.org/10.1016/j.
esmoop.2020.100005; P ¼ 0.026, CL ¼ 0.63). In addition,
high neutrophil-to-lymphocyte ratio (NLR) at day 0 was
found to be associated with O2 (Supplementary Figure S2I,
available at https://doi.org/10.1016/j.esmoop.2020.100005;ring infection in the Manchester cohort (****P < 0.0001). (B) Lymphocyte count
t (***P < 0.001). (C) Boxplot of day 0 lymphocyte count (total cohort) grouped by
us 7 days during infection in the Manchester cohort (***P ¼ 0.0008). (E) Platelet
*P ¼ 0.03). (F) Boxplot of lymphocyte count according to worst outcome in the
COVID-19 reason, inpatient due to reason other than COVID-19 and outcome not
equire oxygen; admitted plus O2, admitted due to COVID-19 and required oxygen;
-19 death, death due to other. (G) Boxplot of lymphocyte count grouped by
e count grouped by whether patient died in the entire cohort measured at day 0.
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Figure 2. Longitudinal changes in neutrophils.
(A) Boxplot of neutrophil count according to worst outcome in the entire cohort
measured at day 0. Discharge, discharged within 24 hours; Inpt for non-COVID-19
reason, inpatient due to reason other than COVID-19 and outcome not altered
by infection; COVID-19 no O2, admitted due to COVID-19 infection but did not
require oxygen; admitted plus O2, admitted due to COVID-19 and required ox-
ygen; admitted plus ICU, admitted due to COVID-19 and required intensive care;
COVID-19 death, death due to other. (B) Boxplot of neutrophil count grouped by
oxygen requirement in the entire cohort measured at day 0. (C) Boxplot of
neutrophil count grouped by death in the entire cohort measured at day 0. (D)
Boxplot of whether the given G-CSF grouped by oxygen requirement in the
Manchester cohort measured at day 0. (E) Boxplot of whether the given G-CSF
grouped by death in the Manchester cohort measured at day 0. COVID-19,
coronavirus disease 2019; G-CSF, granulocyte colony-stimulating factor; ICU,
intensive care unit.
ESMO Open R. J. Lee et al.P ¼ 0.001, CL ¼ 0.67) and death (Supplementary Figure S2J,
available at https://doi.org/10.1016/j.esmoop.2020.100005;
P ¼ 0.01, CL ¼ 0.59), as was the rate of rise (O2: P ¼ 0.003;
CL ¼ 0.75, Supplementary Figure S2K, available at https://
doi.org/10.1016/j.esmoop.2020.100005; death: P ¼ 0.004;
6 https://doi.org/10.1016/j.esmoop.2020.100005CL ¼ 0.81, Supplementary Figure S2L, available at https://
doi.org/10.1016/j.esmoop.2020.100005). Critically, in pa-
tients treated with G-CSF, we did not observe increased
numbers requiring oxygen or dying (O2: P ¼ 0.44; OR ¼
0.38, Figure 2D; and death: P ¼ 0.33; OR ¼ 0.0, Figure 2E).
Finally, as many cancer treatments and cancer itself can
result in neutropaenia, we assessed whether low neutro-
phils preinfection were associated with outcome. Again, we
did not find a significant association between O2 or death
and CHRONIC average count preinfection (Supplementary
Figure S2M and S2N, available at https://doi.org/10.1016/
j.esmoop.2020.100005; P ¼ 0.8; CL ¼ 0.52 and P ¼ 0.56;
CL ¼ 0.56, O2 and death, respectively) or IMMED (last value
preinfection; Supplementary Figure S2O and S2P, available
at https://doi.org/10.1016/j.esmoop.2020.100005; P ¼
0.55; CL ¼ 0.53 and P ¼ 0.5; CL ¼ 0.54, O2 and death,
respectively).
Biochemical features
C-reactive protein. As CRP, an acute phase protein, is
associated with inflammation,16 we examined this at day
0 according to worst outcome (Figure 3A). At diagnosis of
COVID-19, in all cohorts, raised CRP was significantly asso-
ciated with O2 (Figure 3B; P < 0.001, CL ¼ 0.72) and death
(Figure 3C; P < 0.001, CL ¼ 0.66) from COVID-19. Critically,
different CRP trajectories were observed when comparing
patients longitudinally (Figure 3D). Patients not requiring
oxygen clustered together and had low CRP levels, which
remained flat over time. Those requiring oxygen had high
day 0 but subsequently stable CRP levels, whereas those
patients who died had high day 0 CRP or rapidly increasing
CRP levels (Figure 3D). Furthermore, rate of CRP increase
was significantly associated with O2 or death
(Supplementary Figure S3A, available at https://doi.org/
10.1016/j.esmoop.2020.100005; P ¼ 0.013; CL ¼ 0.71 and
Supplementary Figure S3B, available at https://doi.org/10.
1016/j.esmoop.2020.100005; P ¼ 0.009; CL ¼ 0.77, O2
and death respectively). These data suggest that high
baseline CRP or rapidly rising CRP was associated with poor
outcomes in COVID-19.
As both high neutrophil count and CRP were associated
with worse outcomes and may represent deranged in-
flammatory processes, we examined whether they corre-
lated at day 0 in the entire cohort. We did not observe a
correlation between CRP and neutrophil count. Intriguingly
we found that although patients with low CRP and low
neutrophil count had better outcomes following infection,
patients with either a high CRP/low neutrophil count or a
low CRP but high neutrophil count had worse outcomes
(Figure 3E). This suggests heterogeneous inflammatory re-
sponses in patients with cancer and COVID-19, which can all
result in oxygen requirement and death.
Albumin.We found that that lower albumin at timeof COVID-
19 diagnosis was associated with both O2 (Figure 4A;
P< 0.001, CL¼ 0.71) and death due to COVID-19 (Figure 4B;
P < 0.001, CL ¼ 0.63). In the Manchester cohort, albumin
levels significantly dropped from pre-COVID-19 infectionVolume 6 - Issue 1 - 2021
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versus 35; P < 0.0001; Figure 4C, CL ¼ 0.71), suggesting that
low albumin was associated with an acute phase response to
the viral illness rather than systemic effects from tumour
burden.
Lactate dehydrogenase. Raised LDH has been associated
with increased COVID-19 severity, in addition to increased
tumour burden and aggressive clinical course in cancer
patients.17 We therefore assessed whether LDH changed
during COVID-19 compared with the potential effect of
cancer burden causing a raised LDH prior to infection. In the
Manchester cohort, LDH significantly rose from pre-COVID-
19 infection (IMMED) to the average 7 days during infection
(mean 242 versus 336; P < 0.0001, CL ¼ 0.73, Figure 4D).
Preinfection LDH (day e15) was not associated with worse
outcome (Supplementary Figure S4A, available at https://
doi.org/10.1016/j.esmoop.2020.100005; P ¼ 0.51, CL ¼
0.55 and Supplementary Figure S4B, available at https://doi.
org/10.1016/j.esmoop.2020.100005; P ¼ 0.56, CL ¼ 0.56
for O2 and death, respectively).
We observed that higher LDH at the time of COVID-19
diagnosis was associated with both O2 (Figure 4E; P <
0.001, CL ¼ 0.72) and death due to COVID-19 (Figure 4F;
P ¼ 0.008, CL ¼ 0.69). In addition, similar to CRP, longitu-
dinal analysis of LDH revealed a high day 0 value, which was
more sustained during COVID-19 in patients requiring oxy-
gen or who died compared with those who had a mild
disease course (Figure 4G). Although patients did not clus-
ter together in LDH trajectories as clearly as CRP mea-
surements (Figure 4G), rate of LDH rise was also found to be
significantly associated with O2 and death (Supplementary
Figure S4D, available at https://doi.org/10.1016/j.
esmoop.2020.100005; P ¼ 0.001, CL ¼ 0.78 and
Supplementary Figure S4E, available at https://doi.org/10.
1016/j.esmoop.2020.100005; P ¼ 0.002, CL ¼ 0.83 for O2
and death, respectively).Multivariable analyses
Finally, we evaluated both the day 0 haematological and
biochemical parameters together with clinical factors such
as age, sex, comorbidities, haematological/solid cancer, and
systemic treatment within the preceding 4 weeks
(Supplementary Table S1, available at https://doi.org/10.
1016/j.esmoop.2020.100005). In the univariable analysis of
clinical features, only age (P < 0.001) and total number of
comorbidities (P < 0.001) were significant for O2, whereas
age (P < 0.001), total number of comorbidities (P < 0.01),
male sex (P ¼ 0.047) and haematological cancer (P ¼ 0.02)Figure 3. Longitudinal changes in C-reactive protein.
(A) Boxplot of CRP according to worst outcome in the entire cohort measured at day 0
due to reason other than COVID-19 and outcome not altered by infection; COVID-19
plus O2, admitted due to COVID-19 and required oxygen; admitted plus ICU, admitted d
(B) Boxplot of CRP grouped by oxygen requirement in the entire cohort measured at
measured at day 0. (D) Heatmap of the CRP level (darker red¼ higher CRP) against tim
row and each column by a timepoint. Hierarchical clustering is based on values from d
the entire cohort. Blue, required oxygen; red, did not require oxygen; triangle, died
disease 2019; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; ICU
8 https://doi.org/10.1016/j.esmoop.2020.100005were significantly associated with death. In multivariable
analysis of all day 0 haematological, biochemical and clinical
features presented in Supplementary Table S1, available at
https://doi.org/10.1016/j.esmoop.2020.100005, age (P ¼
0.002), haematological cancer (P ¼ 0.034), CRP (P ¼ 0.004),
NLR (P ¼ 0.036) and albumin (P ¼ 0.02) remained signifi-
cant predictors of death. In addition, multivariable analysis
of time to death from hospital admission (n ¼ 81 patients)
revealed that higher neutrophils (P ¼ 0.027) and advanced
cancer stage (P ¼ 0.042) were associated with earlier death
(Supplementary Table S6, available at https://doi.org/10.
1016/j.esmoop.2020.100005).DISCUSSION
Although numerous studies have examined COVID-19 fea-
tures associated with severity of infection, many of these
have been in noncancer populations and thus may not
represent the specific characteristics of patients with can-
cer. The two largest series to date, in almost 2000 patients
with cancer, have reported that age, male sex, Eastern
Cooperative Oncology Group (ECOG) performance status,
smoking status and presence of other comorbidities such as
hypertension were significantly associated with COVID-19
mortality.4,5 In addition, the COVID-19 and Cancer Con-
sortium (CCC19) study showed that active cancer was
associated with increased mortality, with patients with
progressive disease having the worst outcomes.5 Age was a
significant independent risk factor in both cohorts,4,5 which
again we validated further as a significant predictor of
mortality in our cohort. Notably, neither study showed that
type of cancer treatment received prior to infection was
associated with increased severity of illness.
Analyses of large data sets have shown that patients with
cancer have more severe outcomes when infected with
COVID-19 compared with noncancer populations.3,9 Our
study provides further insight into preinfection character-
istics of patients with cancer and changes during COVID-19.
We observed that both LDH and albumin significantly
changed during infection with SARS-CoV-2 compared with
levels immediately preinfection. Low albumin at presenta-
tion in particular was significantly associated with poor
outcome and this remained significant in multivariable
analysis. In addition, rate of LDH rise was associated with
increased severity, although this should be interpreted with
caution, as fewer data points were available in those
with better outcomes. LDH is a nonspecific marker of cell
damage and death, is widely distributed throughout the
body18 and increases in a number of inflammatory pro-
cesses including ARDS.18 Albumin is an acute phase protein. Discharge, discharged within 24 hours; Inpt for non-COVID-19 reason, inpatient
no O2, admitted due to COVID-19 infection but did not require oxygen; admitted
ue to COVID-19 and required intensive care; COVID-19 death, death due to other.
day 0. (C) Boxplot of CRP grouped by whether patient died in the entire cohort
e (pre/post SARS-CoV-2-positive PCR test). Each patient record is represented by a
ay 0 to 7. (E) Scatter graph of CRP versus neutrophil count measured at day 0 in
from non-COVID-19 cause; cross, died due to COVID-19. COVID-19, coronavirus
, intensive care unit; SARS-CoV, severe acute respiratory syndrome coronavirus 2.
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ESMO Open R. J. Lee et al.that typically decreases during inflammation due to
capillary leakage.19,20 Both are affected by inflammatory
processes associated with cancer, with high LDH also
reflecting high turnover of tumour cells and low albumin
also associated with poor nutritional state and losses
through processes such as accumulation of ascites.17 How-
ever, in our cohort, levels of either LDH or albumin pre-
infection were not associated with COVID-19 severity. Thus,
it appears that changes seen were associated with response
to SARS-CoV-2 itself, rather than pre-existing inflammatory
processes associated with cancer.
Consistent with previous reports,3,21,22 we found that
CRP was associated with increased COVID-19 severity and
this remained significant in multivariable analysis. Rate of
CRP rise was associated with increased severity of illness,
thus patients with high and rising CRPs should be moni-
tored closely, with early discussion about escalation of care.
Intriguingly, CRP is not typically associated with viral in-
fections, suggesting a specific underlying inflammatory
biology related to the host response to SARS-CoV-2.23
Emerging preclinical data have implicated a deranged
inflammatory cascade with increase in interleukin-6 (IL-6),
IL-10, monocyte-chemoattractant protein-1 and interferon
gamma-induced protein 10 associated with worse
outcome.24,25 Notably, we observed that CRP was not
correlated with neutrophil count and that response to
SARS-CoV-2 was heterogeneous, with some patients with
severe outcomes having increased CRP and others pre-
dominantly a neutrophilia, although patients with both high
CRP and high neutrophil count commonly did poorly. Thus
patients with higher neutrophils should be monitored even
if CRP is low. Further understanding of this heterogeneous
response may provide insight into personalising immuno-
modulatory therapies according to the predominant
mechanism of immune dysregulation.
Many patients and clinicians are concerned about the
potential impact of cancer treatments on the immune
system resulting in increased severity of infection. Lower
lymphocytes and neutrophils prior to or during infection
were not associated with increased COVID-19 mortality,
although lower lymphocytes were associated with oxygen
requirement. In addition, high NLR was significantly asso-
ciated with death. Lymphopaenia (<1  109/l) has been
associated with increased severity of COVID-19 (with and
without cancer) in a meta-analysis of 4911 patients.21 The
observation that many patients were already lymphopaenic
prior to infection may explain the lack of a significant
difference in COVID-19 mortality of day 0 lymphocytes in
our population. However, this may explain why cancer
patients as a group are more susceptible to more severe
COVID-19 as lymphocytes were not only low prior to(A) Boxplot of albumin grouped by oxygen requirement in the entire cohort measure
cohort measured at day 0. (C) Albumin IMMED (last test preinfection) versus 7 days d
test preinfection) versus 7 days during infection in the Manchester cohort (****P < 0.
UK cohorts measured at day 0. (F) Boxplot of LDH grouped by whether patient died in
(darker red ¼ higher LDH) against time (pre/post SARS-CoV-2-positive PCR test). Each
clustering is based on values from day 0 to 7. LDH, lactate dehydrogenase; SARS-Co
10 https://doi.org/10.1016/j.esmoop.2020.100005diagnosis, but also they significantly dropped during
COVID-19 infection with the majority being lymphopaenic
at day 0 (247/286). In addition, patients with haemato-
logical cancer had lower lymphocyte counts at day
0 compared with those with solid tumours and in multi-
variate analysis they were more likely to die (P ¼ 0.034; OR
2.0; 95% CI 1.05-3.79). This is supported by data from the
UKCCMP that patients with haematological cancer have
worse outcomes to COVID-19.26 Further comparisons of
preinfection lymphocyte counts of cancer patients versus
noncancer patients, changes during SARS-CoV-2 infection
and correlation with viral load would be required to
definitively test this hypothesis.
By contrast, and consistent with other noncancer co-
horts,24 patients with higher neutrophil counts had poorer
outcomes following presentation of COVID-19. Although
this was not significant in multivariate analysis, higher
neutrophil counts at day 0 were significantly associated
with decreased time from admission to death. Of note,
neutrophil counts associated with severe outcome at day
0 (and even maximal counts during illness) were the upper
quartile of normal or not much higher than normal range.
Although neutrophil counts were increased by G-CSF, it was
not associated with severe outcome, potentially due to the
timing of neutrophilia or immaturity of neutrophils. How-
ever, another study has shown that G-CSF was associated
with worse outcome in 16 patients.27 Thus, use of G-CSF for
neutropaenia during SARS-CoV-2 infection for patients at
risk from serious infectious complications from neu-
tropaenic sepsis as per American Society of Clinical
Oncology (ASCO) guidelines could still be considered but
should be used with caution.28 Neutrophils are associated
with inflammation and increase in response to inflamma-
tory cytokines such as IL-6, which have been shown to be
raised during COVID-19.23,29 Neutrophilia has also been
observed to be a poor prognostic marker in noncancer
patients and aberrant neutrophil extracellular trap forma-
tion may contribute to organ damage in COVID-19.21,30 A
neutrophil activation signature has been associated with
mortality in patients with COVID-19 and critically, preceded
severe illness, suggesting neutrophil activation as important
in the pathogenesis of severe outcome.31 Furthermore, high
neutrophil-to-T-cell ratio has been associated with
increased COVID-19 severity21,24 and we observed worse
outcomes in patients with higher NLRs. Taken together, our
data reveal that patients with higher neutrophil counts or
high NLRs at admission should be monitored carefully.
Others have shown no impact of cancer treatment type
on severity of COVID-19.4,5 We did not observe further
complications in patients who resumed therapy (including
high-dose chemotherapy) following SARS-CoV-2 infection,d at day 0. (B) Boxplot of albumin grouped by whether patient died in the entire
uring infection in the Manchester cohort (****P < 0.0001). (D) LDH IMMED (last
0001). (E) Boxplot of LDH grouped by oxygen requirement in the Manchester and
the Manchester and UK cohorts measured at day 0. (G) Heatmap of the LDH level
patient record is represented by a row and each column a timepoint. Hierarchical
V-2, severe acute respiratory syndrome coronavirus 2.
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still observed high mortality rates in our cohorts and cancer
diagnosis is an independent risk factor for poor outcome.3,9
Other aspects of cancer, such as the effect of disease on
frailty or performance status may therefore be more
important. Critically, many cancer patients with late-stage
disease and consequently poor overall prognosis are not
always suitable candidates for intensive care, which may
also affect outcomes. Large-scale analyses of all patients
undergoing cancer treatments and comparisons of clinico-
pathological features with noncancer populations will
enable better identification of those at highest risk of
COVID-19 infection and adverse outcome. Our data suggest
that low neutrophil counts resulting from cancer or its
treatment are not associated with increased severity of
COVID-19, particularly in patients with solid tumours and
that restarting therapy in patients is safe.
Data were limited to routine tests available, thus other
inflammatory markers such as D-dimers have not been
described. In addition, more detailed analysis of immune
cell subsets and their functional states would improve un-
derstanding of the biology of the different responses of
cancer patients to SARS-CoV-2, although they will not be
able to capture preinfection states. Furthermore, due to the
retrospective nature of this study, data were not available
from each patient for all parameters. LDH was only
routinely collected for the Manchester cohort and some
hospitals within the UK cohort (described in Supplementary
Table S1, available at https://doi.org/10.1016/j.esmoop.2020.
100005). Further prospective studies are therefore needed
to validate our findings fully.
Through longitudinal dissection of biochemical and hae-
matological parameters in patients with cancer, we show
that the features described here prior to infection do not
appear to be associated with worse outcomes in patients
presenting to hospital. However, COVID-19 results in het-
erogeneous inflammatory changes from baseline, which are
associated with severe outcomes for cancer patients. High
CRP, LDH and low albumin were associated with oxygen
requirement and death from COVID-19. Critically, neutro-
philia and not low neutrophils was associated with severity
of COVID-19. Taken together, our data and those of large
cohorts4,5 provide evidence that immunosuppression in
terms of neutrophil counts seen in patients due to cancer
and its treatments is not associated with worse outcome
when infected by SARS-CoV-2, particularly in patients with
solid tumours. However, differences in other immune cell
subsets may still contribute to more severe illness. Our
study adds to the understanding of the dynamic changes
that occur in cancer patients infected with SARS-CoV-2
admitted to hospital and how these are associated with
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